CYP1B1遗传多态性与个体化治疗

doi:10.12092/j.issn.1009-2501.2018.11.019

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (11): 1309-1316.doi: 10.12092/j.issn.1009-2501.2018.11.019

CYP1B1遗传多态性与个体化治疗

陈彬尧¹，李玲^1，2，赵慧佳¹，刘晓红¹，齐振华¹，孙功鹏¹，郝卓文¹，范志鹏¹，董礼¹，乐江²，叶啟发^1，3

¹武汉大学中南医院，武汉大学肝胆疾病研究院，武汉大学移植医学中心，移植医学技术湖北省重点实验室，武汉 430071，湖北；²武汉大学基础医学院药理教研室，武汉 430071，湖北；³中南大学湘雅三医院，卫生部移植医学工程技术研究中心，长沙 410013，湖南

收稿日期:2018-06-26 修回日期:2018-08-01 出版日期:2018-11-26 发布日期:2018-11-22
通讯作者: 叶啟发，男，教授、主任医师，研究方向：肝胆外科，器官移植。 Tel: 027-67812988 E-mail: yqf_china@163.com
作者简介:陈彬尧，女，本科，研究方向：器官移植术后并发症的个体化治疗。 Tel:18671020366 E-mail:chenbinyao_whu@163.com 李玲，并列第一作者，女，博士研究生在读，主管药师，研究方向：器官移植术后并发症的个体化治疗。 Tel:15387041070 E-mail: wh001019@whu.edu.cn
基金资助:
2016年湖北省技术创新专项（2016ACA155）；病毒学国家重点实验室开放研究基金资助项目（2018KF005）；湖北省卫计委药护技和管理专项（WJ2017H0024）

Relevance of CYP1B1 genetic polymorphism and individual therapy

CHEN Binyao ¹, LI Ling ^1,2, ZHAO Huijia ¹, LIU Xiaohong¹, QI Zhenhua¹, SUN Gongpeng¹, HAO Zhuowen¹, FAN Zhipeng¹, DONG Li ¹, YUE Jiang ², YE Qifa ^1,3

¹Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei 430071, Wuhan, China; ²Department of Pharmacology, Basic Medical School of Wuhan University, Hubei 430071, Wuhan, China; ³The 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013, Hunan, China

Received:2018-06-26 Revised:2018-08-01 Online:2018-11-26 Published:2018-11-22

摘要/Abstract

摘要：

CYP1B1是细胞色素P450（cytochrome P450, CYP450s）家族成员，作为I相代谢酶，主要通过催化性激素、脂肪酸、维生素、褪黑素及外源性化学物质和药物的代谢，参与人体组织正常结构和生理功能的维持。研究发现，CYP1B1基因多态性会影响其蛋白表达水平和酶活性，对其催化的代谢过程产生影响，尤其是对性激素和外源物质的代谢过程的改变，与青光眼、各类癌症的发生发展及治疗密切相关。研究CYP1B1参与的机体代谢途径及基因多态性对其影响，有利于深入了解代谢途径的改变在相关疾病发生发展和药物治疗中的作用，加深对癌症、青光眼等疾病的认识，促进从基因层面检测和评估相关疾病的发生风险和预后，从而实现疾病的预防和早期发现，为个体化治疗提供依据，改善患者生存质量，延长生存期。本文拟就近五年CYP1B1参与的主要代谢途径及基因多态性对其影响的研究进展作一综述。

关键词: CYP1B1, 代谢, 基因多态性, 癌症, 青光眼

Abstract:

CYP1B1 is a member of the cytochrome P450 (CYP450s) family. As a phase I metabolizing enzyme, CYP1B1 is involved in the maintenance of normal structure and physiological function in the human body through catalyzing the metabolism of hormones, fatty acids, vitamins, exogenous chemicals and drugs. It has been found that CYP1B1 gene polymorphism can affect its protein expression and enzyme activity, thus having an impact on the metabolic processes that it catalyzes, especially the changes in the metabolic processes of sex hormones and exogenous substances which are closely related to the occurrence and treatment of glaucoma, various types of cancer and other diseases. Studying on the metabolic pathways involving CYP1B1 and on the influence of its gene polymorphisms will help us understand the role of metabolic pathway changes in the development of related diseases and in the medical treatment, deepen our understanding of diseases such as cancer and glaucoma, and facilitate the detection and assessment of the risk of diseases at the genetic level, so as to achieve early detection and prevention of the diseases, to provide evidence for personalized medicine, thus improving the quality of life and prolonging the survival period. This article reviews the research progress of metabolic pathways involving CYP1B1 and the impact of genetic polymorphisms in recent five years.

Key words: CYP1B1, metabolism, genetic polymorphism, cancer, glaucoma

中图分类号:

R968
R394

陈彬尧，李玲，赵慧佳，刘晓红，齐振华，孙功鹏，郝卓文，范志鹏，董礼，乐江，叶啟发. CYP1B1遗传多态性与个体化治疗[J]. 中国临床药理学与治疗学, 2018, 23(11): 1309-1316.

CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.

参考文献

［1］Li F, Zhu W, Gonzalez FJ, et al. Potential role of CYP1B1 in the development and treatment of metabolic diseases［J］. Pharmacol Ther, 2017, 178:18-30.
［2］Banerjee A, Chakraborty S, Chakraborty A, et al. Functional and Structural Analyses of CYP1B1 Variants Linked to Congenital and Adult-OnsetGlaucoma to Investigate the Molecular Basis of These Diseases［J］. PLoS One, 2016, 11(5):e0156252.
［3］Go RE, Hwang KA, Choi KC, et al. Cytochrome P450 1 family and cancers［J］. J Steroid Biochem Mol Biol, 2015,47:24-30.
［4］Xu Q, Chen J, Wei Z, et al. Sex hormone metabolism and threatened abortion［J］. Med Sci Monit, 2017, 23:5041-5048.
［5］Cavalieri E, Rogan E.The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity［J］. Mol Aspects Med, 2014 ,36:1-55.
［6］Callahan CL, Bonner MR, Nie J, et al. Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors［J］. Environ Res, 2018, 161:418-424.
［7］Casto KV, Edwards DA. Testosterone, cortisol, and human competition［J］. Horm Behav, 2016,82:21-37.
［8］Casado FL. The aryl hydrocarbon receptor relays metabolic signals to promote cellular regeneration［J］. Stem Cells Int, 2016,2016:4389802.
［9］Hsu MH, Baer BR, Rettie AE, et al. The crystal structure of cytochrome P450 4B1 (CYP4B1) monooxygenase complexed with octane discloses several structural adaptations for ω-hydroxylation［J］. J Biol Chem, 2017, 292(13):5610-5621.
［10］Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation［J］. Pharmacol Ther, 2013,138(1):103-141.
［11］Chawla B, Swain W, Williams AL, et al. Retinoic acid maintains function of neural crest-derived ocular and craniofacial structures in adult zebrafish［J］. Invest Ophthalmol Vis Sci, 2018,59(5):1924-1935.
［12］Larsen MC, Bushkofsky JR, Gorman T, et al. Cytochrome P450 1B1: An unexpected modulator of liver fatty acid homeostasis［J］. Arch Biochem Biophys, 2015,571:21-39.
［13］Li F, Zhu W, Gonzalez FJ. Potential role of CYP1B1 in the development and treatment of metabolic diseases［J］. Pharmacol Ther, 2017,178:18-30.
［14］Williams AL, Eason J, Chawla B, et al. Cyp1b1 regulates ocular fissure closure through a retinoic acid-independent pathway［J］. Invest Ophthalmol Vis Sci, 2017,58(2):1084-1097.
［15］Mookherjee S, Acharya M, Banerjee D, et al. Molecular basis for involvement of CYP1B1 in MYOC upregulation and its potential implication inglaucoma pathogenesis［J］. PLoS One, 2012,7(9):e45077.
［16］Zhao Y, Wang S, Sorenson CM, et al. Cyp1b1 mediates periostin regulation of trabecular meshwork development by suppression ofoxidative stress［J］. Mol Cell Biol,2013,33(21):4225-4240.
［17］Lewis CJ, Hedberg-Buenz A, DeLuca AP, et al. Primary congenital and developmental glaucomas［J］. Hum Mol Genet, 2017,26(R1):R28-R36.
［18］Wang L, Li Z, Jin L, et al. Indoor air pollution and neural tube defects: effect modification by maternal genes［J］. Epidemiology, 2014,25(5):658-665.
［19］Bolton JL, Dunlap T. Formation and biological targets of quinones: cytotoxic versus cytoprotective effects［J］. Chem Res Toxicol, 2017,30(1):13-37.
［20］He Y, Chevillet JR, Liu G, et al. The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs［J］. Br J Pharmacol, 2015,172(11):2733-2747.
［21］Zahid M, Beseler CL, Hall JB, et al. Unbalanced estrogen metabolism in ovarian cancer［J］. Int J Cancer, 2014, 134(10):2414-2423.
［22］Jiang W, Sun G, Xiong J, et al. Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis［J］. Diagn Pathol, 2014, 9:113.
［23］Duran R, Cravo-Laureau C. Role of environmental factors and microorganisms in determining the fate of polycyclic aromatic hydrocarbons in the marine environment［J］. FEMS Microbiol Rev, 2016, 40(6):814-830.
［24］Hardonnière K, Saunier E. The environmental carcinogen benzo［a］pyrene induces a Warburg-like metabolic reprogramming dependent on NHE1 and associated with cell survival［J］. Sci Rep, 2016,6:30776.
［25］Baugh EH, Ke H. Why are there hotspot mutations in the TP53 gene in human cancers［J］? Cell Death Differ, 2018, 25(1):154-160.
［26］Vineis P, Veglia F, Garte S, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladderand in myeloid leukemias in nonsmokers［J］. Ann Onco, 2007,18(7):1230-1242.
［27］Schults MA, Chiu RK, Nagle PW, et al. Genetic polymorphisms in catalase and CYP1B1 determine DNA adduct formation bybenzo(a)pyrene ex vivo［J］. Mutagenesis, 2013,28(2):181-185.
［28］Gu CY, Li GX, Zhu Y, et al. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk andtelomere length［J］. J Cancer, 2018, 9(2):269-274.
［29］Liu C, Cui H, Gu D, et al. Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies［J］. Lung Cancer, 2017, 113:18-29.
［30］Price DK, Chau CH, Till C, et al. Association of androgen metabolism gene polymorphisms with prostate cancer risk andandrogen concentrations: Results from the Prostate Cancer Prevention Trial［J］. Cancer, 2016,122(15):2332-2340.
［31］Haddad SA, Lunetta KL, Ruiz-Narváez EA, et al. Hormone-related pathways and risk of breast cancer subtypes in African American women［J］. Breast Cancer Res Treat, 2015, 154(1):145-154.
［32］Lopes BA, Emerenciano M, Goncalves BA, et al. Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 are associated with early age acuteleukemia［J］. PLoS One, 2015,10(5):e0127308.
［33］Jin J, Lin F, Liao S, et al. Effects of SNPs (CYP1B1*2 G355T, CYP1B1*3 C4326G, and CYP2E1*5 G-1293C), smoking, anddrinking on susceptibility to laryngeal cancer among Han Chinese［J］. PLoS One, 2014,9(10):e106580.
［34］Li C, Long B, Qin X, et al. Cytochrome P1B1 (CYP1B1) polymorphisms and cancer risk: a meta-analysis of 52 studies［J］. Toxicology, 2015,327:77-86.
［35］Maurya SS, Katiyar T, Dhawan A, et al. Gene-environment interactions in determining differences in genetic susceptibility to cancer in subsites of the head and neck［J］. Environ Mol Mutagen, 2015,56(3):313-321.
［36］Teng Y, He C, Zuo X, et al. Catechol-O-methyltransferase and cytochrome P-450 1B1 polymorphisms and endometrial cancer risk: a meta-analysis［J］. Int J Gynecol Cancer, 2013,23(3):422-430.
［37］Christensen CH, Barry KH, Andreotti G, et al. Sex steroid hormone single-nucleotide polymorphisms, pesticide use, and the risk of prostate cancer: a nested case-control study within the agricultural health study［J］. Front Oncol, 2016,6:237.
［38］Li Y, Tan SQ, Ma QH, et al. CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women［J］. Tumour Biol, 2013,34(6):3561-3567.
［39］Do T, Shei W, Chau PT, et al. CYP1B1 and MYOC Mutations in Vietnamese Primary Congenital Glaucoma Patients［J］. J Glaucoma, 2016,25(5):e491-498.
［40］Gong B, Qu C, Li X, et al. Mutation spectrum of CYP1B1 in Chinese patients with primary open-angle glaucoma［J］. Br J Ophthalmol, 2015,99(3):425-430.
［41］Wang L, Li Z, Jin L, et al. Indoor air pollution and neural tube defects: effect modification by maternal genes［J］. Epidemiology, 2014,25(5):658-665.
［42］Miki Y, Hata S, Ono K, et al. Roles of aryl hydrocarbon receptor in aromatase-dependent cell proliferation in human osteoblasts［J］. Int J Mol Sci, 2017,18(10):2159.
［43］Li C, Wang Z, Wang Q, et al. Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model［J］. Oncotarget, 2017,9(3):3338-3352.
［44］Laroche-Clary A, Le Morvan V, Yamori T, et al. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studieswith in vitro models［J］. Mol Cancer Ther, 2010, 9(12):3315-3321.
［45］Cavaco I, Piedade R, Msellem MI, et al. Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands［J］. Trop Med Int Health, 2012, 17(7):854-857.
［46］Stewart DA, Winnike JH, McRitchie SL, et al. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences［J］. J Proteome Res, 2016,15(9):3225-3240.
［47］Reinhart JM, Motsinger-Reif A, Dickey A, et al. Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials［J］. PLoS One, 2016,11(6):e0156000.

[1]	杜彩凤, 毛宇楠, 高嘉, 王娟, 李小叶, 田俊生, 刘宏奇. 基于1H-NMR代谢组学的绝经期综合征血清代谢标志物研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 961-968.
[2]	游蓉丽, 黄玉荣, 毛睿, 海丽娜, 王颖莉, 王艳. 基于血清代谢组学与网络药理学探究复方苦参注射液治疗肺癌的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(9): 988-999.
[3]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[4]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[5]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[6]	谢晶晶, 尹鸿涛, 刘进进, 孙蔚明, 甄东户. 基线血清25-羟维生素D3水平与代谢综合征发病风险的前瞻性队列研究[J]. 中国临床药理学与治疗学, 2023, 28(6): 641-652.
[7]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[8]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[9]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[10]	蔡祖欢, 邓桃妹, 魏奶杰, 朱丹, 钱斐, 王广基, 张经纬. 水飞蓟宾改善非酒精性脂肪性肝炎小鼠脂质代谢紊乱[J]. 中国临床药理学与治疗学, 2023, 28(3): 241-248.
[11]	石丹丹, 孙祎尧, 陈晓琦, 杨芳明, 张传雷, 王新亭, 袁长威, 陈欣菊. 扶正消瘤颗粒治疗原发性肝癌的疗效观察及血清代谢组学分析[J]. 中国临床药理学与治疗学, 2023, 28(11): 1247-1262.
[12]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[13]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[14]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.
[15]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.

CYP1B1遗传多态性与个体化治疗

Relevance of CYP1B1 genetic polymorphism and individual therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价